About This Trial
Real-world effectiveness study in diverse patient population.
Primary Endpoints
- IGA 0/1 response
- EASI-75 achievement
Latest Update
January 2026
Approved in EU and US. Real-world data confirms efficacy with convenient monthly dosing.